- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02719405
Impact of Infant Formula on Resolution of Cow's Milk Allergy
A Prospective Randomized Controlled Trial to Evaluate the Effect of Infant Formula on the Resolution of Cow's Milk Allergy of Infancy
Primary Endpoint
-The percentage of subjects who develop tolerance to cow's milk protein by 12 months post randomization to study formula.
Secondary Endpoints
Tolerance
- The transcriptional profile of milk-specific T cells by clinical outcome.
- Growth and Weight Velocity
- Stool Consistency and Frequency
- The estimated frequency of milk-specific T cells by clinical outcome.
- The TCR diversity of milk-specific T cells by clinical outcome.
- The milk allergen component-specific IgE, IgG4 and IgA by clinical outcome.
Safety
- The rate of reported adverse events by treatment group.
Study Overview
Status
Conditions
Detailed Description
Cow's Milk Allergy (CMA) is prevalent and most often presents during infancy. Disease manifestations vary through a range of immediate and delayed inflammatory responses to milk protein from anaphylaxis to enterocolitis. The natural history is also highly variable; most children will achieve clinical tolerance early in life, while a minority will have disease persisting to adulthood for reasons that are not known. Most presentations are mild and are managed by restriction or reduction of immunologically intact milk protein with reintroduction sometime after a year of age; however, there are data to suggest that some level of antigenic stimulation may be beneficial. Furthermore, recent data suggest that oral probiotic exposure may also promote tolerance, though the kinetics of tolerance acquisition, the interaction between these two factors (probiotics and milk antigen exposure) and their relationship to regulatory T cell responses are all poorly defined. Therefore, there is an unmet need to identify dietary interventions, along with corresponding immune responses, that favor the promotion of tolerance.
A major objective will be to measure the effect probiotics have on the development of tolerance to milk antigen over time. By following these infants during the first year of life, and repeatedly collecting blood and stool samples from them, we will be poised to analyze their stool microbiome signatures, and we will estimate the frequency, phenotype and TCR diversity of milk-specific T cells over time. By repeatedly challenging them with more immunologically intact milk protein, we will better define the kinetics of CMA resolution and its association to these variables. This information is likely to further elucidate CMA disease mechanisms and identify possible biomarkers of disease resolution versus persistence. It will be directly useful for evaluating the efficacy of probiotics and hydrolyzed formula for promoting milk tolerance.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
Woburn, Massachusetts, United States, 01801
- Woburn Pediatric Associates
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria (to consent):
- Infants 0-120 days of age with suspected CMA, as determined by the pediatrician or specialist, will be referred to the study. A Standard Operating Procedures (SOP) document will be provided for the clinicians to help guide their referral to the study. Physician diagnosis of CMA will be based on the following:
- Physician documented, gross or persistent microscopic blood in stool (3 positive guaiac cards on three separate stools) in the absence of other explanation (e.g., fissure, moderate-to-severe constipation) AND / OR
Infant with at least one gastrointestinal, dermatological, or respiratory allergic manifestation suggestive of CMA:
- Gastrointestinal: Chronic Diarrhea, Constipation or Vomiting/Gastro-esophageal reflux
- Dermatologic: Atopic Dermatitis or Urticaria
- Respiratory: Cough, Allergic rhinitis or Recurrent Wheezing
- General:Colic / Irritability
- No change in treatment with medications during the 7 days preceding the elimination diet and no expected change in medications during the DBPCFCs (unless otherwise medically necessary)
- Signed informed consent obtained for infants participation in the study
- Signed authorization obtained to use and/or disclose Protected Health Information for infant from birth through the length of the study period
Willingness to comply with following inclusion criteria if found to have a positive DBPCFC screen:
- Caregiver(s) agree to comply with the infant elimination diet given to them by the investigator for the duration of the study
- Mother agrees to follow an elimination diet throughout duration of breast feeding
- Parent(s) or legally authorized representative agrees not to enroll infant in another interventional clinical study while participating in this study
Inclusion Criteria (to randomization):
- Positive Double Blind Placebo Controlled Food Challenge (DBPCFC).
Exclusion Criteria (to consent):
- History of anaphylaxis to milk
- Use of probiotics
- Use in the previous 4 weeks of systemic steroids
- Use of systemic immunomodulatory treatment, including biologics with an immune target such as Xolair
- Known eosinophilic GI disorders
- Episode(s) of severe repetitive vomiting and lethargy prompting an emergency room visit and occurring within 4 hours of ingesting a milk protein (i.e. consistent with FPIES)
- Co-existing autoimmune or other chronic disease or serious health problem, including celiac disease, inflammatory bowel disease, malignancy, congenital, metabolic or genetic disorders or malformations
- Intention to exclusively breast feed
- Infants born at less than 36 weeks gestation (35 weeks + 6 days is considered 35 weeks gestation)
Exclusion Criteria (to randomization):
- Severe reaction to Milk Protein during the DBPCFC
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Amino Acid Formula
|
Amino Acid Formula
|
Active Comparator: EHCF
Extensively Hydrolyzed Casein Formula
|
Extensively Hydrolyzed Casein Formula
|
Active Comparator: EHCF + LGG
Extensively Hydrolyzed Casein Formula + Lactobacillus GG
|
Extensively Hydrolyzed Casein Formula
Lactobacillus GG
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The percentage of subjects who develop tolerance to cow's milk protein by 12 months post randomization to study formula.
Time Frame: 12 months post randomization
|
12 months post randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety as assessed by adverse events graded using the NCI-CTCAE scale by treatment group.
Time Frame: 36 months
|
The rate of reported adverse events by treatment group.
|
36 months
|
Tolerance as assessed by the transcriptional profile of milk-specific T cells by clinical outcome.
Time Frame: 36 months
|
36 months
|
|
Tolerance as assessed by weight for age Z-scores.
Time Frame: 36 months
|
36 months
|
|
Tolerance as assessed by length for age Z-scores.
Time Frame: 36 months
|
36 months
|
|
Tolerance as assessed by weight for length Z-scores.
Time Frame: 36 months
|
36 months
|
|
Tolerance as assessed by stool consistency using the Bristol Stool Chart.
Time Frame: 36 months
|
36 months
|
|
Tolerance as assessed by stool frequency.
Time Frame: 36 months
|
36 months
|
|
Tolerance as assessed by changes in the stool microbiome.
Time Frame: 36 months
|
36 months
|
|
Tolerance as assessed by the estimated frequency of milk-specific T cells by clinical outcome.
Time Frame: 36 months
|
36 months
|
|
Tolerance as assessed by the TCR diversity of milk-specific T cells by clinical outcome.
Time Frame: 36 months
|
36 months
|
|
Tolerance as assessed by the milk allergen component-specific IgE, IgG4 and IgA by clinical outcome.
Time Frame: 36 months
|
36 months
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2015P000962
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Milk Allergy
-
Martini Hospital GroningenRecruitingCow Milk Allergy | Food AllergyNetherlands
-
University GhentActive, not recruitingCow Milk Allergy | Food AllergyBelgium
-
Federico II UniversityUnknown
-
Federico II UniversityRecruiting
-
Société des Produits Nestlé (SPN)Completed
-
Assistance Publique - Hôpitaux de ParisESPCI ParisCompleted
-
University of Campinas, BrazilCompleted
-
Universitaire Ziekenhuizen KU LeuvenRecruitingCow Milk Allergy | Food AllergyBelgium
-
Assiut UniversityUnknown
Clinical Trials on Amino Acid Formula
-
Société des Produits Nestlé (SPN)Completed
-
Laboratorios OrdesaOPBG Clinical & Research Services S.R.L.Completed
-
Mead Johnson NutritionTerminated
-
Federico II UniversityCompleted
-
United PharmaceuticalsCompleted
-
Peking University Third HospitalCancer Institute and Hospital, Chinese Academy of Medical Sciences; Beijing... and other collaboratorsRecruitingCow Milk Allergy | Food Allergy in ChildrenChina
-
Société des Produits Nestlé (SPN)CompletedShort Bowel Syndrome | Cow's Milk Protein Allergy | Eosinophilic Gastrointestinal Disorders | Malabsorption/Maldigestion | Multiple Food AllergiesUnited States
-
United PharmaceuticalsCompletedCow Milk AllergyItaly